Two different sides of 'chemobrain': Determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study

Psycho-Oncology

Volumn 19, Issue 12, 2010, Pages 1321-1328

  Hermelink, Kerstin ^a   Küchenhoff, Helmut ^a   Untch, Michael ^b   Bauerfeind, Ingo ^c   Lux, Michael Patrick ^d   Bühner, Markus ^a   Manitz, Juliane ^a   Fensterer, Veronika ^a   Münzel, Karin ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b HELIOS Clinic Berlin Buch   (Germany)

^c Klinikum Landshut   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

adverse effects; antineoplastic combined chemotherapy protocols; cancer; cognition disorders; neuropsychological tests; oncology

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; LETROZOLE; METHOTREXATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; TAMOXIFEN;

ADULT; AFFECT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CLINICAL ASSESSMENT; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; OUTCOME ASSESSMENT; PERCEPTION; PREOPERATIVE CARE; PROSPECTIVE STUDY; PSYCHOLOGIC TEST; RATING SCALE; SELF REPORT; STATISTICAL SIGNIFICANCE;

EID: 78649958408     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.1695     Document Type: Article

References (39)

1. Ahles TA, Saykin AJ, McDonald BC, et al,. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 2008; 110 (1): 143-152.
2. Cimprich B, So H, Ronis DL, Trask C,. Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psycho-Oncology 2005; 14 (1): 70-78.
3. Harder H, Van Gool AR, Cornelissen JJ, et al,. Assessment of pre-treatment cognitive performance in adult bone marrow or haematopoietic stem cell transplantation patients: a comparative study. Eur J Cancer 2005; 41 (7): 1007-1016.
4. Schagen SB, Boogerd W, Muller MJ, et al,. Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer chemotherapy. Acta Oncol 2008; 47 (1): 63-70.
5. Jansen CE, Dodd MJ, Miaskowski CA, Dowling GA, Kramer J,. Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psycho-Oncology 2008; 17 (12): 1189-1195.
6. Mehnert A, Scherwath A, Schirmer L, et al,. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns 2007; 66 (1): 108-118.
7. Shilling V, Jenkins V,. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 2007; 11 (1): 6-15.
8. Hermelink K, Untch M, Lux MP, et al,. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 2007; 109 (9): 1905-1913. (Pubitemid 46668557)
9. Downie FP, Mar Fan HG, Houede-Tchen N, Yi Q, Tannock IF,. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psycho-Oncology 2006; 15 (10): 921-930.
10. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA,. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 2004; 26 (7): 955-969.
11. Poppelreuter M, Weis J, Kulz AK, Tucha O, Lange KW, Bartsch HH,. Cognitive dysfunction and subjective complaints of cancer patients a cross-sectional study in a cancer rehabilitation centre. Eur J Cancer 2004; 40 (1): 43-49.
12. Ahles TA, Saykin AJ, Furstenberg CT, et al,. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002; 20 (2): 485-493.
13. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF,. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999; 85 (3): 640-650.
14. van Dam FS, Schagen SB, Muller MJ, et al,. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90 (3): 210-218.
15. Cull A, Hay C, Love SB, Mackie M, Smets E, Stewart M,. What do cancer patients mean when they complain of concentration and memory problems? Br J Cancer 1996; 74 (10): 1674-1679.
16. Schilder CM, Eggens PC, Seynaeve C, et al,. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol 2009; 48 (1): 76-85.
17. Bender CM, Pacella ML, Sereika SM, et al,. What do perceived cognitive problems reflect? J Support Oncol 2008; 6 (5): 238-242.
18. Costa Jr PT, McCrae RR,. Hypochondriasis, neuroticism, and aging: when are somatic complaints unfounded? Am Psychol 1985; 40 (1): 19-28.
19. Pennebaker JW,. The Psychology of Physical Symptoms. Springer: New York, 1982.
20. Costa Jr PT, McCrae RR,. Neuroticism, somatic complaints, and disease: is the bark worse than the bite? J Pers 1987; 55 (2): 299-316.
21. Watson D, Pennebaker JW,. Health complaints, stress, and distress: exploring the central role of negative affectivity. Psychol Rev 1989; 96 (2): 234-254.
22. Watson D, Clark LA,. Negative affectivity: the disposition to experience aversive emotional states. Psychol Bull 1984; 96 (3): 465-490.
23. Schagen SB, Das E, van Dam FS,. The influence of priming and pre-existing knowledge of chemotherapy-associated cognitive complaints on the reporting of such complaints in breast cancer patients. Psycho-Oncology 2009; 18 (6): 674-678.
24. Hermelink K, Henschel V, Untch M, Bauerfeind I, Lux MP, Munzel K,. Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study. Cancer 2008; 113 (9): 2431-2439.
25. Untch M, Fasching PA, Bauerfeind I, et al,. The PREPARE trial A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin/cyclophosphamide followed by paclitaxel±darbepoetin alfa in primary breast cancer: A preplanned interim analysis of efficacy at surgery. J Clin Oncol 2008; 26: May (20 suppl); abstr517.
26. Aaronson NK, Ahmedzai S, Bergman B, et al,. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85 (5): 365-376.
27. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, Group obotEQoL. The EORTC QLQ-C30 Scoring Manual (3 edn.) European Organisation for Research and Treatment of Cancer: Brussels, 2001.
28. Suslow T, Arolt V, Junghanns K,. Differentielle Validität des Fragebogen erlebter Defizite der Aufmerksamkeit (FEDA): konkurrente Validierungsergebnisse bei schizophrenen und depressiven Patienten. Zeitschrift für Klinische Psychologie, -Psychiatrie und -Psychotherapie 1998; 46 (2): 152-165.
29. Härting C, Markowitsch HJ, Neufeld H, Calabrese P, Deisinger K, Kessler J,. WMS-R. Wechsler Gedächtnistest-Revidierte Fassung (2 edn.). Verlag Hans Huber: Bern Göttingen Toronto Seattle, 2004.
30. Tewes U,. HAWIE-R. Hamburg-Wechsler Intelligenztest für Erwachsene, Revision 1991 (2 edn.). Verlag Hans Huber: Bern Göttingen Toronto Seattle, 1994.
31. Brickenkamp R,. Test d2. Aufmerksamkeits-Belastungs-Test (9 edn.). Hogrefe Verlag: Göttingen, 2002.
32. Reitan RM,. Trail Making Test (2 edn.) Reitan Neuropsychology Laboratory: Tucson AZ, 1992.
33. Aschenbrenner S, Tucha O, Lange KW,. RWT. Regensburger Wortflüssigkeits-Test. Hogrefe-Verlag: Göttingen, 2000.
34. Lehrl S,. Mehrfachwahl-Wortschatz-Intelligenztest MWT-B. Spitta: Balingen, 1999.
35. Herrmann C, Buss U, Snaith RP,. HADS-D. Hospital Anxiety and Depression Scale-Deutsche Version (1 edn.). Verlag Hans Huber: Bern, Göttingen, Toronto, Seattle, 1995.
36. Watson D, Clark LA, Tellegen A,. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 1988; 54 (6): 1063-1070.
37. Krohne H-W, Egloff B, Kohlmann C-W, Tausch A,. Untersuchungen mit einer deutschen Version der 'Positive and Negative Affect Schedule' (PANAS). Diagnostica 1996; 42 (2): 139-156.
38. Crawford JR, Henry JD,. The positive and negative affect schedule (PANAS): construct validity, measurement properties and normative data in a large non-clinical sample. Br J Clin Psychol 2004; 43 (Pt 3): 245-265.
39. Mora PA, Halm E, Leventhal H, Ceric F,. Elucidating the relationship between negative affectivity and symptoms: the role of illness-specific affective responses. Ann Behav Med 2007; 34 (1): 77-86.